Oral and intravenous pharmacokinetic profiles of doxofylline in patients with chronic bronchitis.
Serum doxofylline concentrations were evaluated after solid-phase extraction by high-performance liquid chromatography following administration of 100 mg doxofylline given as a single intravenous dose over 10 min or 400 mg doxofylline given orally twice daily for 5 days in six and eight non-smoking, fasting, chronic bronchitic patients, respectively. Doxofylline possessed a very short distribution phase following intravenous administration, with a sustained elimination phase (half-life 1.83 +/- 0.37 h). After oral administration, the peak serum doxofylline concentration was 15.21 +/- 1.73 micrograms/ml and the mean elimination half-life was 7.01 +/- 0.80 h; there was a large inter-subject variability. No side-effects were experienced by the patients during the study.
Bologna
E
E
Clinical Pharmacology Unit, San Giovanni Calibita Hospital, Rome, Italy.
Laganà
A
A
Terracino
D
D
Bolignari
P
P
Biffignandi
P
P
D000284:Administration, Oral; D000368:Aged; D000996:Antitussive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D002908:Chronic Disease; D005260:Female; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D013806:Theophylline / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use
D000996:Antitussive Agents; D013806:Theophylline; C029797:doxofylline